HPV infection
Exam relevance: in 27 of more than 150 board exam reports · rank 29
- Synonyms
- human papillomavirus, HPV
- Specialty
- Gynaecology · Cervix & HPV
- Images
- Clinical 3 · Histology & cytology 1
- Exam relevance
- 27 of more than 150 reports · rank 29
- In the app
- 1 flashcard · GynFuchs
- Last updated
- 10/2026 · Dr. Pascal Bafteh
Contents
Images (4)

Histology & cytology

Definition
- HPV infection is an infection of cutaneous or mucosal epithelial cells by human papillomaviruses.
- HPV is the most common sexually transmitted infection; anogenital types can also reach the oropharynx through orogenital contact.
Classification
HPV types
- High-risk types most often expected: 16 and 18, plus 31, 33, 45, 52, 58.
- Low-risk types and their typical disease: 6 and 11 — condylomata acuminata.
- HPV 16 and 18 together cause roughly 70 % of cervical cancers.
- More than 100 HPV types are known; most infect the skin and cause skin warts, while others mainly infect the mucosa of the anogenital region and of the oropharynx and larynx.
- The low-risk types 6 and 11 most often cause anogenital warts as well as laryngeal and oropharyngeal warts.
- Virtually all cervical cancers are caused by HPV: about 70 % are due to HPV 16 and 18, and many of the rest to the high-risk types 31, 33, 45, 52 and 58.
Occurrence & epidemiology
Epidemiology
- Almost all sexually active people are infected with HPV at some point in their lives, usually without symptoms.
- Infection usually has no lasting effects: the immune system generally clears HPV within a year or two.
- Persistent infection with high-risk types causes cervical cancer and is associated with cancers of the vulva, vagina, mouth and throat, penis and anus; cervical cancer is the most common HPV-related cancer and accounts for over 90 % of HPV-related cancers in women.
Aetiopathogenesis
What the virus does
- The viral oncoproteins E6 and E7 inactivate p53 (via E6) and the retinoblastoma protein pRb (via E7).
- The consequence of pRb inactivation is overexpression of p16 — hence p16 as the immunohistochemical surrogate marker.
- In vulvar cancer this becomes the classification: uVIN is p16-positive and HPV-associated, dVIN is p53-altered and lichen-associated.
Aetiology and risk factors
- In stratified squamous epithelium such as the ectocervix, the virus reaches the basal cells through a wound; in the transformation zone, reserve cells beneath the single layer of columnar cells are thought to be particularly susceptible.
- In the basal cells the viral genome is maintained as a low-copy-number episome; integration into the host genome is not part of the normal viral life cycle but a pathological event in some persistent infections.
- The oncoprotein E6 causes degradation of p53 and E7 inactivates pRb; deregulated expression of E6 and E7 leads to cell-cycle disruption and genomic instability.
- Smoking favours persistent infection; HPV is more prevalent among, for example, women living with HIV and immunocompromised individuals.
Clinical features
Transmission and course
- Transmission: sexual, including skin-to-skin contact without penetration.
- The great majority of infections clear spontaneously within one to two years.
- What determines cancer risk is persistence of a high-risk type — not a single positive test.
More facts from the study questions
- The viral oncoprotein E6 inactivates the tumour suppressor protein p53.
- The viral oncoprotein E7 inactivates the retinoblastoma protein pRb.
- HPV-associated uVIN (usual-type VIN) is p16-positive.
- In contrast, p53 mutation is characteristic of dVIN (differentiated VIN), which is associated with lichen sclerosus.
- The high-risk types HPV 16 and 18 are the most common causative agents.
- Together they cause approximately 70% of all cervical carcinomas.
- The inactivation of pRb by the viral E7 protein leads to a compensatory overexpression of p16.
- This mechanism makes p16 a reliable surrogate marker.
- A large proportion of infections are successfully eliminated by the immune system.
- The crucial carcinoma risk stems from a persistent infection, not from a single positive test.
- Most infected people have no symptoms.
- Genital warts appear after an incubation period of 1 to 6 months; they may be painful, itchy or bleed.
- In women, warts occur most commonly on the vulva, vaginal wall, cervix and perineum; with reduced cell-mediated immunity, for example in pregnancy or HIV infection, they may persist and spread widely.
- Persistent high-risk infections lead via cellular changes and precursor lesions to cancer; cervical cancer usually takes 15–20 years to develop.
- Early cellular changes and precursor lesions mostly cause no symptoms; HPV 16 and 18 usually cause endocervical or anal intraepithelial lesions that are difficult to see clinically.
Diagnosis
- Genital warts are usually diagnosed by visual inspection; atypical, bleeding, ulcerated or persistent warts may be biopsied to exclude carcinoma.
- At the cervix, nucleic acid amplification tests for oncogenic HPV types and cytology (Pap smear) are used; initial tests typically detect 13 common high-risk types.
- Cervical and anal intraepithelial lesions can be visualised only by colposcopy or anoscopy; on contact with 3 to 5 % acetic acid, they turn white and become easier to detect.
Treatment principles
- There is no causal treatment for HPV infection; most infections clear spontaneously over time.
- The consequences are treated: genital warts with topical or ablative therapy, and cervical dysplasia according to findings, ranging from surveillance to conisation, assessed through screening and the colposcopy clinic.
- HPV vaccination protects against new infection with the included types but does not treat an existing infection.
Specific treatment regimens with drugs and doses are covered in the GynFuchs app.
Keep learning in the app
Further reading (selection)
Cross-references
Keep learning
Keep learning with flashcards, exam questions and spot diagnoses in the GynFuchs app – free, in your browser or as an app.
Related pages: Cervical dysplasia (CIN) · Cervical cancer · Cervical polyp and ectropion
Note: Learning content from the GynFuchs app (flashcards, exam questions, image cases) for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.